Thousands of men with advanced prostate cancer are set to benefit from the first at-home treatment in what has been hailed a 'major advance' for the disease. Relugolix has been given the go-ahead ...

Novartis has secured its first approval in Europe for prostate cancer radioligand therapy Pluvicto, getting a green light from the UK Medicines and Healthcare products Regulatory Agency (MHRA).